University of Oxford Featured PhD Programmes
University of Leeds Featured PhD Programmes
University of Oxford Featured PhD Programmes

Enabling better reporting of outcomes for breast cancer radiotherapy trials

PhD Programmes

This project is no longer listed on and may not be available.

Click here to search for PhD studentship opportunities
Prof J Bliss , Prof C Coles No more applications being accepted Funded PhD Project (Students Worldwide)

About the Project

Technology-enabled data collection is a rapidly-developing field in routine clinical practice and within clinical trials. This has primarily two strands i) collecting data directly from patients via electronic patient-reported outcomes (ePRO) using technology-based user friendly solutions such as smartphone apps [1], and ii) emerging opportunities for trials to link with routinely-collected NHS data. Whilst the merits of the goal are obvious, achieving that goal is challenging for multiple reasons. These include governance / data access issues and difficulties with collection of recurrence data from routine sources for cancer clinical trials. In addition, the ePRO is not always user-friendly or deemed cost effective or sufficiently inclusive for the trial-specific patient population and/or type of data being requested.

Outcomes relevant to breast cancer radiotherapy trials
As for any medical treatment, radiotherapy for breast cancer has to balance clinical benefit in terms of treating the cancer against minimising treatment-related adverse effects. Hence important outcomes in breast cancer radiotherapy trials include disease-related efficacy outcomes, i.e. recurrence and survival, as well as radiotherapy-related adverse effects. These radiotherapy adverse effects are usually termed “normal tissue effects” (NTE) as they relate to the healthy normal tissues that may receive some radiation dose when the area around where the tumour site is treated. These normal tissue effects can occur in the short-term (during and shortly after radiotherapy) and tend to resolve quickly, but long-term effects can occur up to many years following radiotherapy. Although rates of these so-called late normal tissue effects have declined following developments in radiotherapy techniques, they remain prevalent (around 25% may experience a moderate/marked adverse effect in the treated breast by 5 years following radiotherapy), and can be permanent (e.g. breast shrinkage), potentially having a long-term impact on patients. Severe radiotherapy-related adverse effects such as cardiac or lung disease are rare, but clearly clinically important. In the era of very low disease event rates (around 2% of patients experience a recurrence of the cancer in their breast within 5 years) it is even more imperative to minimise treatment-related adverse effects, and hence appropriate measurement of these effects within clinical trials is essential.

For details on how to apply using our online recruitment portal please see Please note we only accept applications via the online application system

Funding Notes

Candidates should hold, or, expect to gain either;

First, or, upper-second class honours degree (or equivalent) in a relevant subject.
A masters degree in a relevant subject.

Successful candidates will undertake a three-year research training programme under the guidance of a supervisory team of our world-class researchers, starting in January 2021 unless otherwise specified. Students will receive an annual stipend, currently £21,000 per annum, as well as having fees and project costs paid for the three-year duration.

We particularly welcome applicants from British Black and ethnic minority backgrounds, as they are under-represented at PhD level within the ICR and nationwide.
Search Suggestions

Search Suggestions

Based on your current searches we recommend the following search filters.

FindAPhD. Copyright 2005-2020
All rights reserved.